Rezatapopt等小分子药物的研发旨在修复p53并重新激活其抑癌功能。早期研究显示Rezatapopt疗效显著，但与大多数靶向疗法一样，患者最终可能会产生耐药性。近日，麻省总医院等机构的研究人员开展了一项新研究，发现了导致Rezatapopt治疗产生临床耐药性的突变机制。

本研究针对p53在血管生成过程中调控内皮细胞命运的剂量效应机制不明确的问题，通过药理学激活p53，首次揭示了低浓度p53 ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

Researchers identified a novel mechanism by which expression of the tumor suppressor p53 paradoxically promotes liver cancer development in patients with chronic liver disease. By generating a mouse ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...

A new hypothesis article was published in Oncotarget (Volume 17) on January 3, 2026, titled “Hypothesis: HPV E6 and COVID ...